Use of the Neurotoxic Component of a Botulinum Toxin

Abstract

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

1 . A method for treating a disease, disorder or condition, the method comprising the step of administering to a patient with a disease, disorder or condition an effective amount of the neurotoxic component of a botulinum toxin, wherein the neurotoxic component has a molecular weight of about 150 kilodaltons, thereby treating the disease, disorder or condition.  
     
     
         2 . The method of  claim 1  wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.  
     
     
         3 . The method of  claim 1  wherein the botulinum toxin is botulinum toxin type A.  
     
     
         4 . The method of  claim 1  wherein the neurotoxic component is administered by intramuscular injection.  
     
     
         5 . The method of  claim 1  wherein the disease, disorder or condition is associated with a facial muscle.  
     
     
         6 . The method of  claim 5  wherein the disease, disorder or condition is facial grimacing.  
     
     
         7 . The method of  claim 6  wherein the method markedly reduces the facial grimacing.  
     
     
         8 . A method for treating a facial disease, disorder or condition, the method comprising the step of administering to a patient with a facial disease, disorder or condition an effective amount of the neurotoxic component of a botulinum toxin type A, wherein the neurotoxic component has a molecular weight of about 150 kilodaltons, thereby treating the facial disease, disorder or condition.  
     
     
         9 . The method of  claim 8  wherein the facial disease, disorder or condition is facial grimacing.  
     
     
         10 . The method of  claim 9  wherein the method reduces the facial grimacing.  
     
     
         11 . A method for treating a facial disease, disorder or condition, the method comprising the step of administering to a patient with a facial disease, disorder or condition an effective amount of the neurotoxic component of only a botulinum toxin type A, wherein the neurotoxic component has a molecular weight of about 150 kilodaltons, thereby treating the facial disease, disorder or condition.  
     
     
         12 . A method for treating a facial disease, disorder or condition, the method comprising the step of administering to a patient with a facial disease, disorder or condition an effective amount of the neurotoxic component from a single botulinum toxin type selected from the group consisting of the botulinum toxin types A, B, C, D, E, F and G, wherein the neurotoxic component has a molecular weight of about 150 kilodaltons, thereby treating the facial disease, disorder or condition.